FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burd	len									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					UI	Section	11 30(1	11) 01 111	e ilives	suneni	. Company .	ACT OF	1 1940								
1. Name ar		2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC [TNDM									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)										
<u>Leal James</u>																Directo			10% O		
(Loct) (Eirct) (Middle)						1										Officer below)	(give title	Other (specify below)		specify	
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)									SVP, Operations						
C/O TANDEM DIABETES CARE, INC.						07/27/2021															
11075 ROSELLE STREET						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street)						, = 1. , = 1. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.									Line)						
SAN DIEGO CA 92121															X Form filed by One Reporting Person Form filed by More than One Reporting						
					-										Person						
(City)	(S	tate)	(Zip)																		
		Tab	le I -	Non-Deri	vative	e Sec	uriti	ies A	cquir	ed, I	Dispose	d of,	, or B	Beneficia	lly (Owned	t				
1. Title of	Security (Ins	tr. 3)		2. Transaction		2A. De			3.		4. Securitie					5. Amo				7. Nature	
Date (Month/Day/Ye						Execution Date, if any (Month/Day/Year)		,	Transaction Disposed Code (Instr. 8)		Of (D)) (Instr.	3, 4 and 5)	Benefic			(D) o	r Indirect	Beneficial Ownership		
								rear,	.		Amount (A) or Puice			Report					(Instr. 4)		
								Code	٧			9)	Price			str. 3 and 4)					
Common	Stock			07/27/20)21	1			M ⁽¹⁾		1,666		Α	\$51.5	51.5		5,262		D		
Common	Stock			07/27/20)21				S ⁽²⁾		1,666		D	\$102.250	4 ⁽³⁾	3	,596		D		
		Т	able	II - Deriva	ative	Secu	ritie	s Ac	auire	d. Di	sposed	of. o	or Be	neficiall	v O	wned					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)			5. Number of Derivative Securities		ivative	6. Date Exercisable and Expiration Date (Month/Day/Year)			A	7. Title and Amount of Securities Underlying		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficial		10. Ownershi Form: Direct (D)	11. Nature of Indirect Beneficial Ownership	
	Derivative Security						Acquired (A) or Disposed of (D) (Instr. 3, 4						Derivative Sect (Instr. 3 and 4)			·	Owned Following Reported Transactio (Instr. 4)	on(s)	or Indirect (I) (Instr. 4)	t (Instr. 4)	
							and 5)		-			+	ļ .		-						
									Date		Expiration			Amount or Number of							
			_		Code	V	(A)	(D)	Exerc	cisable	Date	Ti	Title	Shares	\vdash						
Stock Option	\$51.5	07/27/2021			M			1,666	'	(4)	(5)		Common Stock	ⁿ 1,666	\$	51.5	31,667	·	D		

Explanation of Responses:

- 1. Represents shares of common stock received upon exercise of a stock option award.
- 2. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020.
- 3. The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$102.17 to \$102.26. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- 4. The options vested as to twenty-five percent (25%) of the underlying shares on 2/15/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").
- 5. The expiration date for these options is 10 years from the date of grant.

Remarks:

s/ David B. Berger, Attorneyin-Fact for James A. Leal

07/29/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.